Eye rosacea study seeks safer antibiotic use
NCT ID NCT05296837
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at how different doses of the antibiotic doxycycline affect antibiotic resistance in people with ocular rosacea, an inflammatory eye condition. Researchers will compare a low anti-inflammatory dose (40 mg daily) with a standard antibiotic dose (200 mg daily) and a placebo. The goal is to see which dose causes the least resistance in gut bacteria, helping guide safer long-term treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
doxycycline
What this could lead to
If successful, this study could help doctors choose the safest doxycycline dose for ocular rosacea, reducing the risk of antibiotic resistance.
What could go wrong
This is a small, early-phase study focused on measuring resistance, not on treating symptoms. Results may not change current practice directly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTIMICROBIAL RESISTANCE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of California, San Farncisco
San Francisco, California, 94143, United States